The North America BNP and NT-proBNP Market would witness market growth of 10.1% CAGR during the forecast period (2022-2028).
Non-cardiogenic and cardiogenic origins of dyspnea in an emergency is the strongest rationale for BNP monitoring. In substantially all cases of CHF aggravation, dyspnea is a symptom. It is not, however, exclusive to CHF and might be brought on by other pathologic diseases. About 97% of patients with heart failure can be detected with BNP. Thus, a healthy BNP level should stimulate an investigation for noncardiac explanations of dyspnea and essentially rule out heart failure.
Conversely, an increased level of BNP may signal the existence of heart disease and the requirement for additional cardiac testing, such as echocardiography, to identify the cause of the patient's condition. Longer hospital stays have also been linked to short-term increases in hospitalized individuals with CHF. Individuals with greater New York Heart Association operational class scores have elevated levels of BNP, which are associated with morbidity and mortality as well as repeated hospitalization.
BNP can also be a helpful prognostic marker in people with known CHF. Also, it has been demonstrated that short-term BNP spikes predict longer hospital stays in hospitalized heart failure patients. A key factor in mortality after myocardial infarction (MI) is left ventricular (LV) dysfunction brought on by cardiac remodeling. In patients experiencing post-MI LV dysfunction and ejection fractions 40%, BNP becomes increased, which makes it possible to monitor BNP to assess prognosis after MI.
The Pan American Heart Organization (PAHO) estimates that cardiovascular diseases (CVD) in this region result in 40.8 million DALYs (disability-adjusted life years) each year. 89% of all CVD DALYs were due to premature deaths. Due to population expansion and aging, there will likely be an increase in the overall number of CVD fatalities in the coming years. The two primary underlying illnesses that result in death and disability from CVD are ischemic heart disease (IHD) and stroke. Nearly all of the region's non-high-income countries are experiencing an increase in the burden of CVD, and frighteningly, the age-standardized cardiovascular disease rate has started to increase in many regions where it had been dropping. The regional market would expand as a result of this factor.
The US market dominated the North America BNP and NT-proBNP Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $547.4 Million by 2028. The Canada market is poised to grow at a CAGR of 12.2% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.9% during (2022 - 2028).
Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on Application, the market is segmented into Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF) and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide BNP and NT-proBNP Market is Projected to reach USD 2.2 Billion by 2028, at a CAGR of 11.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMérieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Location of Testing
- Point of Care Testing
- Laboratory Testing
By Application
- Myocardial Infarction
- Acute Coronary Syndrome (ACS)
- Congestive Heart Failure (CHF)
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Siemens AG
- Danaher Corporation
- Gentian Diagnostics ASA
- PerkinElmer, Inc.
- BioMérieux S.A.
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
- F.Hoffmann-La Roche Ltd. (Roche Holding Ltd.)
- Scripps Laboratories
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America BNP and NT-proBNP Market, by Location of Testing
1.4.2 North America BNP and NT-proBNP Market, by Application
1.4.3 North AMeirca BNP and NT-proBNP Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America BNP and NT-proBNP Market by Location of Testing
3.1 North America Point of Care Testing Market by Country
3.2 North America Laboratory Testing Market by Country
Chapter 4. North America BNP and NT-proBNP Market by Application
4.1 North America Myocardial Infarction Market by Country
4.2 North America Acute Coronary Syndrome (ACS) Market by Country
4.3 North America Congestive Heart Failure (CHF) Market by Country
4.4 North America Others Market by Country
Chapter 5. North America BNP and NT-proBNP Market by Country
5.1 US BNP and NT-proBNP Market
5.1.1 US BNP and NT-proBNP Market by Location of Testing
5.1.2 US BNP and NT-proBNP Market by Application
5.2 Canada BNP and NT-proBNP Market
5.2.1 Canada BNP and NT-proBNP Market by Location of Testing
5.2.2 Canada BNP and NT-proBNP Market by Application
5.3 Mexico BNP and NT-proBNP Market
5.3.1 Mexico BNP and NT-proBNP Market by Location of Testing
5.3.2 Mexico BNP and NT-proBNP Market by Application
5.4 Rest of North America BNP and NT-proBNP Market
5.4.1 Rest of North America BNP and NT-proBNP Market by Location of Testing
5.4.2 Rest of North America BNP and NT-proBNP Market by Application
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Siemens AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 SWOT Analysis
6.3 Danaher Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Gentian Diagnostics ASA
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 PerkinElmer, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 BioMérieux S.A.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Quidel Corporation
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Bio-Rad laboratories, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expenses
6.9 F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.)
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Scripps Laboratories
6.10.1 Company Overview
TABLE 1 North America BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 2 North America BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 3 North America BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 4 North America BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 5 North America Point of Care Testing Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Point of Care Testing Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Laboratory Testing Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Laboratory Testing Market by Country, 2022 - 2028, USD Million
TABLE 9 North America BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 10 North America BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 11 North America Myocardial Infarction Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Myocardial Infarction Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Acute Coronary Syndrome (ACS) Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Acute Coronary Syndrome (ACS) Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Congestive Heart Failure (CHF) Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Congestive Heart Failure (CHF) Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 19 North America BNP and NT-proBNP Market by Country, 2018 - 2021, USD Million
TABLE 20 North America BNP and NT-proBNP Market by Country, 2022 - 2028, USD Million
TABLE 21 US BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 22 US BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 23 US BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 24 US BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 25 US BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 26 US BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 27 Canada BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 28 Canada BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 29 Canada BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 30 Canada BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 31 Canada BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 32 Canada BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 33 Mexico BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 34 Mexico BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 35 Mexico BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 36 Mexico BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 37 Mexico BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 38 Mexico BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 39 Rest of North America BNP and NT-proBNP Market, 2018 - 2021, USD Million
TABLE 40 Rest of North America BNP and NT-proBNP Market, 2022 - 2028, USD Million
TABLE 41 Rest of North America BNP and NT-proBNP Market by Location of Testing, 2018 - 2021, USD Million
TABLE 42 Rest of North America BNP and NT-proBNP Market by Location of Testing, 2022 - 2028, USD Million
TABLE 43 Rest of North America BNP and NT-proBNP Market by Application, 2018 - 2021, USD Million
TABLE 44 Rest of North America BNP and NT-proBNP Market by Application, 2022 - 2028, USD Million
TABLE 45 Key Information – Abbott Laboratories
TABLE 46 Key Information – Siemens AG
TABLE 47 Key Information – Danaher Corporation
TABLE 48 Key Information – Gentian Diagnostics ASA
TABLE 49 key Information – PerkinElmer, Inc.
TABLE 50 Key information – BioMérieux S.A.
TABLE 51 key information – Quidel Corporation
TABLE 52 Key Information – Bio-Rad Laboratories, Inc.
TABLE 53 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 54 Key Information – Scripps Laboratories
List of Figures
FIG 1 Methodology for the research
FIG 2 Swot analysis: Abbott laboratories
FIG 3 Swot analysis: Siemens AG